Kamada is no longer a development-stage pipeline story for public-market investors. The equity is a specialty-plasma commercial franchise whose inhaled alpha-1 trial died last December, and the investment debate is whether the remaining cash-generative portfolio compounds on its own or whether partner concentration and a still-empty acquisition pillar keep the multiple compressed. Shares last changed hands near $8.67. That price capitalizes the company at about $500 million.
The load-bearing commercial event of the summer is the three-year plasma supply pact signed in July. Management sold the normal-source output of the Houston and San Antonio collection centers to an unnamed plasma-therapy manufacturer for about $50 million over the contract life. That sale converts idle collection capacity into contracted revenue and, more importantly, proves that the Texas vertical-integration build is a merchant business rather than a captive cost center. First shipments are slated for the fourth quarter and already sit inside the affirmed annual guide.
The tension is concentration, not growth. Kedrion remains the sole United States distributor of KEDRAB, the anti-rabies immunoglobulin that still dominates the proprietary book, and that single counterparty generated roughly 30% of last year's sales. The GLASSIA royalty rate from Takeda already stepped down by half after August of last year. CYTOGAM, the cytomegalovirus immunoglobulin, lost share to oral antivirals. A record first half therefore still sits on a franchise whose profit mix can shift against the shareholder without any single product failing.
The next observable test is whether fourth-quarter plasma shipments actually start and whether the second-half proprietary mix holds the first-half adjusted-EBITDA margin. Management affirmed a full-year revenue range whose midpoint implies low-double-digit growth and an adjusted-EBITDA range whose midpoint implies low-twenties growth, both versus last year's print. If those ranges land without a commercial acquisition, the market is left to decide whether an organic compounder at a high-single-digit earnings multiple is cheap or merely fairly paid for partner risk.